The domestic growth hormone drug market, which is rapidly growing, has faced a variable with the release of new products by major companies. LG Chem, the No. 1 company in the market, replaced the existing Eutropin with the next-generation product, Eutropin S, further solidifying its leading position, followed by Dong-A ST and Pfizer. In particular, Pfizer plans to add NGENLA, a once-a-week medication, to its lineup starting next month. Depending on the success of this product, considerable changes are expected in the growth hormone market in the future.

Expected to exceed 250 billion won in the growth hormone market, successful replacement of LG Chem’s Eutropin S generation. According to IQVIA, a pharmace